Literature DB >> 8648769

Effect of the number of core biopsies of the prostate on predicting Gleason score of prostate cancer.

D Thickman1, W C Speers, P J Philpott, H Shapiro.   

Abstract

PURPOSE: We determined the effect of the number of core biopsies of the prostate on predicting the Gleason score of the prostatectomy specimen.
MATERIALS AND METHODS: The Gleason scores from 124 radical prostatectomy specimens were compared to those from preoperative core needle biopsies of the prostate. The number of cores obtained and tumor stage were compared regarding agreement in prostate cancer score.
RESULTS: Four to 6 core biopsies yielded the best results, with agreement within 1 Gleason score in 75% of the cases. Further increases in the number of core biopsies did not improve results. Additionally, 37% of the well differentiated tumors on core biopsy were stage C.
CONCLUSIONS: Gleason score from the core biopsy has limitations in respect to predicting prostatectomy tumor score and stage and, therefore, it is problematic for use in therapeutic decision making.

Entities:  

Mesh:

Year:  1996        PMID: 8648769

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Correlation between Gleason score of needle biopsy and radical prostatectomy tissue.

Authors:  M Cecchi; R Minervini; C A Sepich; C Ippolito; G L Pagni; D Summonti; A Di Benedetto; L Fiorentini
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

2.  The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer.

Authors:  Al B Barqawi; Ruslan Turcanu; Eduard J Gamito; Scott M Lucia; Colin I O'Donnell; E David Crawford; David D La Rosa; Francisco G La Rosa
Journal:  Int J Clin Exp Pathol       Date:  2011-06-12

3.  Pathological Correlation between Number of Biopsies and Radical Surgery: Does It Make a Difference to Final Pathology?

Authors:  Tahir Qayyum; Jennifer M Willder; Paul G Horgan; Joanne Edwards; Mark A Underwood
Journal:  Curr Urol       Date:  2013-07-28

4.  Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading.

Authors:  A Pichon; Y Neuzillet; H Botto; J-P Raynaud; C Radulescu; V Molinié; J-M Herve; T Lebret
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-10-06       Impact factor: 5.554

5.  The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era.

Authors:  Stavros Sfoungaristos; Ioannis Katafigiotis; Petros Perimenis
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

6.  Pathological correlation between needle biopsy and radical prostatectomy specimen in patients with localized prostate cancer.

Authors:  Muhammad A Bulbul; Yaser El-Hout; Maurice Haddad; Ayman Tawil; Ali Houjaij; Nizar Bou Diab; Oussama Darwish
Journal:  Can Urol Assoc J       Date:  2007-09       Impact factor: 1.862

7.  Needle biopsy size and pathological Gleason Score diagnosis: No evidence for a link.

Authors:  Antonio Cicione; Francesco Cantiello; Cosimo De Nunzio; Andrea Tubaro; Rocco Damiano
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

8.  Importance and determinants of Gleason score undergrading on biopsy sample of prostate cancer in a population-based study.

Authors:  Elisabetta Rapiti; Robin Schaffar; Christophe Iselin; Raymond Miralbell; Marie-Françoise Pelte; Damien Weber; Roberto Zanetti; Isabelle Neyroud-Caspar; Christine Bouchardy
Journal:  BMC Urol       Date:  2013-04-11       Impact factor: 2.264

Review 9.  The role of transrectal ultrasound in diagnosing prostate cancer.

Authors:  Richard Clements
Journal:  Curr Urol Rep       Date:  2002-06       Impact factor: 2.862

10.  Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?

Authors:  Byung-Soo Jin; Seok-Hyun Kang; Duk-Yoon Kim; Hoon-Gyu Oh; Chun-Il Kim; Gi-Hak Moon; Tae-Gyun Kwon; Jae-Shin Park
Journal:  Korean J Urol       Date:  2015-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.